We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
+$98.6M
Cap. Flow
+$39.6M
Cap. Flow %
1.62%
Top 10 Hldgs %
39.51%
Holding
166
New
25
Increased
26
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$38M
2
COR icon
Cencora
COR
+$30.2M
3
CVS icon
CVS Health
CVS
+$22.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21M
5
GILD icon
Gilead Sciences
GILD
+$16M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.3M
3
NVO
Novo Nordisk
NVO
+$16M
4
VTR icon
Ventas
VTR
+$14.3M
5
DOC
PHYSICIANS REALTY TRUST
DOC
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.46%
2 Real Estate 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
26
HCA Healthcare
HCA
$85.7B
$25.8M 1.05%
334,998
– –
MDCO
27
DELISTED
Medicines Co
MDCO
$23.7M 0.97%
704,238
+139,800
+25% +$4.93M
HUM icon
28
Humana
HUM
$44B
$23.3M 0.95%
129,300
– –
JAZZ icon
29
Jazz Pharmaceuticals
JAZZ
$16.2B
$22.1M 0.9%
156,451
-22,640
-13% -$3.34M
A icon
30
Agilent Technologies
A
$39.2B
$22M 0.9%
495,450
-218,400
-31% -$9.42M
CVS icon
31
CVS Health
CVS
$134B
$21.4M 0.87%
+223,891
New +$22.3M
GSK icon
32
GSK
GSK
$104B
$18.8M 0.77%
347,360
+119,360
+52% +$6.29M
UHS icon
33
Universal Health Services
UHS
$9.88B
$18.1M 0.74%
134,680
– –
AZN icon
34
AstraZeneca
AZN
$266B
$17.3M 0.71%
287,000
+109,100
+61% +$6.34M
XBI icon
35
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$15.9M 0.65%
294,000
– –
MDVN
36
DELISTED
MEDIVATION, INC.
MDVN
$15.5M 0.63%
256,638
-410,662
-62% -$23.3M
IBB icon
37
iShares Biotechnology ETF
IBB
$9.52B
$14.8M 0.61%
173,010
– –
NVS icon
38
Novartis
NVS
$301B
$14M 0.57%
189,832
+86,379
+83% +$5.97M
OHI icon
39
Omega Healthcare
OHI
$15B
$14M 0.57%
413,116
– –
MPT
40
Medical Properties Trust
MPT
$2.81B
$14M 0.57%
920,393
-643,667
-41% -$9.11M
DHC
41
Diversified Healthcare Trust
DHC
$2.17B
$14M 0.57%
670,504
– –
MNK
42
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$13.6M 0.56%
223,900
– –
WELL.PRI
43
DELISTED
Welltower Inc.
WELL.PRI
$13.6M 0.55%
200,000
– –
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$27.4B
$13.5M 0.55%
243,995
+106,500
+77% +$6.71M
TMO icon
45
Thermo Fisher Scientific
TMO
$214B
$12.8M 0.52%
86,395
– –
SNY icon
46
Sanofi
SNY
$103B
$12.8M 0.52%
305,000
– –
STJ
47
DELISTED
St Jude Medical
STJ
$12.4M 0.51%
158,805
-97,005
-38% -$6.92M
HZNP
48
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.4M 0.5%
749,900
– –
ZBH icon
49
Zimmer Biomet
ZBH
$18.4B
$12.3M 0.5%
105,369
– –
IDXX icon
50
Idexx Laboratories
IDXX
$44.1B
$12.3M 0.5%
132,352
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tekla Capital Management held 166 positions worth $2.45B, up 4.2% from $2.35B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2016 filing shows 25 new, 26 increased, 19 reduced and 10 closed positions. Its largest new stake was Abbott: 953,500 shares worth $37.5M. The largest sale was Celgene Corp, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2016 buy was Abbott: 953,500 shares worth $37.5M.
  • Tekla Capital Management added most to Neurocrine Biosciences in Q2 2016, an estimated $21M increase.
  • Tekla Capital Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $36M.
  • Tekla Capital Management fully exited Novo Nordisk in Q2 2016, selling an estimated $16M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2016.
  • Tekla Capital Management opened 25 new positions and closed 10 in Q2 2016.
  • Tekla Capital Management's portfolio value rose 4.2% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.